Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
235.46
+9.75 (+4.32%)
Delayed Quote
Updated: 1:40 PM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Discover which S&P500 stocks are making waves on Monday.
↗
Today 12:35 EDT
Via
Chartmill
Biogen (BIIB) Stock Is Up, What You Need To Know
Today 9:50 EDT
What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neut...
Via
StockStory
Topics
Earnings
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
Today 8:35 EDT
Via
Chartmill
2 Surging Stocks for Long-Term Investors and 1 We Brush Off
Today 0:41 EDT
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
Via
StockStory
Topics
Economy
Energy
Therapeutics Stocks Q2 Highlights: Gilead Sciences (NASDAQ:GILD)
October 07, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Gilead Sciences (NASDAQ:GILD)...
Via
StockStory
Topics
Artificial Intelligence
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating
↗
August 17, 2026
Via
Chartmill
1 Profitable Stock Worth Investigating and 2 We Ignore
October 01, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
Via
StockStory
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks
September 30, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers. O...
Via
StockStory
Topics
Artificial Intelligence
Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
September 24, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Bioge...
Via
StockStory
Topics
Artificial Intelligence
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
September 23, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
Via
StockStory
Topics
Artificial Intelligence
Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)
September 21, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its pe...
Via
StockStory
Topics
Artificial Intelligence
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
↗
September 15, 2026
Biogen (NASDAQ:BIIB) is reshaping its business around a broader mix of neuroscience, immunology, kidney disease and ophthalmology assets, President and CEO Chris Viehbacher said during a Morgan Stanley...
Via
MarketBeat
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
↗
September 12, 2026
Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to...
Via
MarketBeat
Thursday's session: top gainers and losers in the S&P500 index
↗
September 10, 2026
Via
Chartmill
Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks
September 09, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASD...
Via
StockStory
Topics
Artificial Intelligence
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
September 08, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove...
Via
StockStory
Topics
Artificial Intelligence
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
September 07, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th...
Via
StockStory
Topics
Artificial Intelligence
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
August 27, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers. Over the next f...
Via
StockStory
Topics
Artificial Intelligence
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
August 25, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how therapeutics stocks fa...
Via
StockStory
Topics
Artificial Intelligence
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
August 25, 2026
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 pe...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
August 19, 2026
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
Via
StockStory
Topics
Artificial Intelligence
Biogen (BIIB) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.
Via
The Motley Fool
Topics
Earnings
The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call
August 05, 2026
Biogen’s second quarter witnessed a positive market response, buoyed by notable revenue growth and a significant beat on non-GAAP profit relative to analysts...
Via
StockStory
Topics
Earnings
Why Supernus Pharmaceuticals Stock Topped the Market Today
↗
August 03, 2026
It's effecting a "merger of equals" with a peer.
Via
The Motley Fool
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
July 30, 2026
Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion...
Via
StockStory
Why Biogen Stock Topped the Market Today
↗
July 29, 2026
The company published its second-quarter results on Wednesday morning.
Via
The Motley Fool
Biogen Q2 Earnings Call Highlights
↗
July 29, 2026
Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results....
Via
MarketBeat
Topics
Earnings
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
July 29, 2026
Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP prof...
Via
StockStory
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
July 27, 2026
Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for. Biogen beat analysts’ revenue exp...
Via
StockStory
Topics
Artificial Intelligence
3 Profitable Stocks We Steer Clear Of
July 21, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
51
52
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
